Burnette P K, Ameer B, Hoang V, Phifer W
College of Pharmacy, University of Florida, Gainesville.
DICP. 1989 May;23(5):382-4. doi: 10.1177/106002808902300506.
Rifampin can be associated with severe adverse effects such as hepatitis, acute renal failure, hemolytic anemia, and thrombocytopenia. Thrombocytopenia has traditionally been associated with intermittent therapy. This article reports the occurrence of rifampin-associated thrombocytopenia in an indigent patient after a four-month lapse in therapy for pulmonary tuberculosis. The patient's platelet count dropped rapidly to a level of 1000/mm3 after receiving a single 600 mg dose of rifampin. After returning to a normal level of greater than 100,000/mm3, the patient's platelets again dropped to 1200/mm3 with readministration of rifampin. The long-term therapy necessary to eradicate the Mycobacterium tuberculosis organism makes economic considerations important. This patient and other indigent patients who may be poor compliers because they are unable to buy the necessary medication may be at a higher risk for adverse reactions.
利福平可能会引发严重的不良反应，如肝炎、急性肾衰竭、溶血性贫血和血小板减少症。传统上，血小板减少症与间歇治疗有关。本文报告了一名贫困患者在中断四个月的肺结核治疗后出现利福平相关血小板减少症的情况。该患者在单次服用600毫克利福平后，血小板计数迅速降至1000/mm³。在恢复到大于100,000/mm³的正常水平后，患者再次服用利福平时血小板又降至1200/mm³。根除结核分枝杆菌所需的长期治疗使得经济因素变得很重要。该患者以及其他可能因无力购买所需药物而依从性差的贫困患者可能发生不良反应的风险更高。
